ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,317.89
-0.07%
Dow Jones
39,840.47
-0.08%
US Dollar vs MXN
16.64235
0.12%
Brent Oil
82.275
-0.21%
Bitcoin
70,230.46
0.14%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Europa
  5. EU
  6. Mithra Pharmaceuticals SA (MITRA)

  7. Mithra Pharmaceuticals SA (MITRA) Noticias

MITRA

Mithra Pharmaceuticals (MITRA)

Mithra Pharmaceuticals SA
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:EU:MITRA
FechaHoraFuenteTítuloSímboloCompañía
03/05/202410:30GlobeNewswire Inc.Mithra enters into exclusive negotiations with Gedeon Richter and secures continued funding in the context of its monetization processEU:MITRAMithra Pharmaceuticals SA
29/04/202400:00GlobeNewswire Inc.Mithra updates on offers received in the context of its monetization process and on its Annual Report 2023EU:MITRAMithra Pharmaceuticals SA
22/04/202400:00GlobeNewswire Inc.Mithra secures court protection measures to advance monetization processEU:MITRAMithra Pharmaceuticals SA
08/03/202400:00GlobeNewswire Inc.Mithra reports full year 2023 financial resultsEU:MITRAMithra Pharmaceuticals SA
05/03/202400:01GlobeNewswire Inc.Mithra announces changes to its executive managementEU:MITRAMithra Pharmaceuticals SA
05/03/202400:00GlobeNewswire Inc.Mithra initiates monetization process, receives bridge loan from existing lendersEU:MITRAMithra Pharmaceuticals SA
29/02/202404:42GlobeNewswire Inc.DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phaseEU:MITRAMithra Pharmaceuticals SA
15/02/202411:23GlobeNewswire Inc.Mithra sells shares in Mayne PharmaEU:MITRAMithra Pharmaceuticals SA
06/02/202400:00GlobeNewswire Inc.Mithra updates on cash positionEU:MITRAMithra Pharmaceuticals SA
21/12/202310:45GlobeNewswire Inc.Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in IsraelEU:MITRAMithra Pharmaceuticals SA
20/12/202310:45GlobeNewswire Inc.Mithra Completes Pediatric Study of ESTELLE® in Adolescent PatientsEU:MITRAMithra Pharmaceuticals SA
18/12/202300:00GlobeNewswire Inc.Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 TrialEU:MITRAMithra Pharmaceuticals SA
04/12/202300:00GlobeNewswire Inc.Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in ChinaEU:MITRAMithra Pharmaceuticals SA
30/11/202300:00GlobeNewswire Inc.Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United StatesEU:MITRAMithra Pharmaceuticals SA
28/11/202310:45GlobeNewswire Inc.Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in AmsterdamEU:MITRAMithra Pharmaceuticals SA
07/11/202300:00GlobeNewswire Inc.Mithra’s NEXTSTELLIS® granted additional patent in the United StatesEU:MITRAMithra Pharmaceuticals SA
06/11/202311:52GlobeNewswire Inc.Mithra releases invitation to its extraordinary securities holders’ meetingEU:MITRAMithra Pharmaceuticals SA
26/10/202300:00GlobeNewswire Inc.Mithra and Searchlight Pharma sign DONESTA® licensing agreement for CanadaEU:MITRAMithra Pharmaceuticals SA
23/10/202300:00GlobeNewswire Inc.Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreementEU:MITRAMithra Pharmaceuticals SA
17/10/202300:00GlobeNewswire Inc.Mithra’s Board of Directors to propose the removal of its request for change of the remuneration policy at the Special General MeetingEU:MITRAMithra Pharmaceuticals SA
11/10/202300:15GlobeNewswire Inc.Shareholder LetterEU:MITRAMithra Pharmaceuticals SA
11/10/202300:00GlobeNewswire Inc.Mithra announces update to the agenda of its upcoming special general shareholders’ meetingEU:MITRAMithra Pharmaceuticals SA
10/10/202311:00GlobeNewswire Inc.Mithra to Hold Presentations on Key Role of Estrogens in Women’s Health, Including Estetrol (E4), at FIGO World CongressEU:MITRAMithra Pharmaceuticals SA
05/10/202300:00GlobeNewswire Inc.Mithra Provides an Update in the Context of Recent Market DevelopmentsEU:MITRAMithra Pharmaceuticals SA
27/09/202300:00GlobeNewswire Inc.Mithra Announces Presentation of Positive Data on Estetrol (E4) Native Estrogen at NAMS 2023EU:MITRAMithra Pharmaceuticals SA
26/09/202300:00GlobeNewswire Inc.Mithra Financial Results for First-Half 2023EU:MITRAMithra Pharmaceuticals SA
22/09/202306:30GlobeNewswire Inc.Mithra présentera ses résultats financiers du premier semestre 2023 à ses investisseurs lors d'une conférence web le 26 septembre à 14 h 00 CETEU:MITRAMithra Pharmaceuticals SA
21/09/202310:55GlobeNewswire Inc.Information on the total number of voting rights (denominator)EU:MITRAMithra Pharmaceuticals SA
21/09/202310:55GlobeNewswire Inc.Mithra to Hold Investor Call on H1 2023 Financial Results on September 26 at 14:00 CESTEU:MITRAMithra Pharmaceuticals SA
12/09/202310:45GlobeNewswire Inc.Notice of Adjustment of the Conversion Price of Mithra's EUR 125,000,000 Senior Unsecured Convertible Bonds due 2025EU:MITRAMithra Pharmaceuticals SA
 Showing the most relevant articles for your search:EU:MITRA

Su Consulta Reciente

NASDAQ
AAPL
Apple
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
AMZN
Amazon.com
FX
USDMXN
US Dollar vs MXN
USI
USTECH100
US Tech 100
CCOM
US500
US 500
NYSE
NKE
Nike
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
KO
Coca Cola
COIN
SOLUSD
Solana
NYSE
DIS
Walt Disney
NYSE
MCD
McDonalds
NASDAQ
TSLA
Tesla
NYSE
AXP
American Express
AMEX
SPY
SPDR S&P 500
CCOM
SILVER
SILVER
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados